Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | October 19, 2026

Oct 19, 2026

•

3 min read

Biotech & Pharma Updates | October 19, 2026

🧬 Merck KGaA acquires Silence Therapeutics for $1.3B, gaining promising siRNA blood cancer drug divesiran, Disc Medicine's (bitopertin) Ph3 trial meets all endpoints for erythropoietic protoporphyria, paving way for FDA resubmission, Sanofi breaks ground on new Frankfurt insulin manufacturing facility, targeting full production by 2032

Christian Cuchapin, +1

The Diseases We Couldn't Afford to Study Until Now

Oct 17, 2026

•

4 min read

The Diseases We Couldn't Afford to Study Until Now

Deciding which diseases are worth studying has never been a purely scientific question. It has always come down to how much evidence one person can hold in their head. AI is changing that.

Anis Fahandej-Sadi

Biotech & Pharma Updates | October 16, 2026

Oct 16, 2026

•

3 min read

Biotech & Pharma Updates | October 16, 2026

🧬 Roche's Enspryng (satralizumab) wins FDA approval for thyroid eye disease, targeting interleukin-6 receptor following Ph3 data, City Therapeutics raises $200M IPO, advancing next-gen RNAi therapies pipeline, Eli Lilly's oral weight-loss pill Foundayo wins EU regulator backing for obesity and type 2 diabetes

Christian Cuchapin, +1

Biotech & Pharma Updates | October 15, 2026

Oct 15, 2026

•

3 min read

Biotech & Pharma Updates | October 15, 2026

🧬 Iambic Therapeutics raises $150M IPO, AI-driven drug discovery targeting HER2-positive solid tumors, FDA expands ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln) label for high-grade papillary non-muscle invasive bladder cancer, AstraZeneca, Insitro partner on MASH and cardiomyopathy drug discovery, $40M upfront, $1.5B total

Christian Cuchapin, +1

Biotech & Pharma Updates | October 14, 2026

Oct 14, 2026

•

3 min read

Biotech & Pharma Updates | October 14, 2026

🧬 Zealand Pharma, Generate:Biomedicines partner on AI-designed obesity, metabolic drugs, up to $1.2B deal, Verastem Oncology's (VS-7375) shows 50% objective response rate in Ph1/2 for KRAS G12D-mutant metastatic pancreatic ductal adenocarcinoma, Soufflé Therapeutics raises $135M Series A to advance three cell-targeted RNA programs into clinic

Christian Cuchapin, +1

Biotech & Pharma Updates | October 13, 2026

Oct 13, 2026

•

4 min read

Biotech & Pharma Updates | October 13, 2026

🧬 GSK pledges $800M to build biologics production facility and innovation hub in Pennsylvania, Asahi Kasei's Hovilpri (pritelivir) wins FDA approval for drug-resistant herpes simplex virus lesions in immunocompromised patients following Ph3 success, Roche, Rona Therapeutics license RNAi-based ALK7 obesity candidate for up to $1.16B

Christian Cuchapin, +1

Biotech & Pharma Updates | October 9, 2026

Oct 9, 2026

•

3 min read

Biotech & Pharma Updates | October 9, 2026

🧬 GSK joins Chai Discovery's AI drug discovery platform following successful wet-lab validation of protein designs, FDA approves Roche's Tecentriq (atezolizumab) for Stage III mismatch repair deficient colon cancer based on Ph3 data, TRex Bio prices $117M IPO to advance immune-regulating Treg-targeted drug pipeline

Christian Cuchapin, +1

Biotech & Pharma Updates | October 8, 2026

Oct 8, 2026

•

3 min read

Biotech & Pharma Updates | October 8, 2026

🧬 Novartis' Rhapsido (remibrutinib) wins FDA label expansion for symptomatic dermographism based on Ph3 data, Viatris to acquire Pacira BioSciences for $1.65B, expanding non-opioid pain management portfolio, Bristol Myers Squibb's Zenbexus (iberdomide) hits Ph3 progression-free survival endpoint in relapsed or refractory multiple myeloma

Christian Cuchapin, +1

Biotech & Pharma Updates | October 7, 2026

Oct 7, 2026

•

3 min read

Biotech & Pharma Updates | October 7, 2026

🧬 Cerevance's (solengepras) meets Ph3 primary endpoint, reducing off time in Parkinson's disease, paving path to FDA, Matchpoint Therapeutics raises $150M Series B to advance covalent medicines pipeline into clinic, GSK's Cabenuva (cabotegravir/rilpivirine) shows superior viral suppression in unsuppressed HIV patients in Ph3 trial

Christian Cuchapin, +1

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | October 19, 2026

The Diseases We Couldn't Afford to Study Until Now

Biotech & Pharma Updates | October 16, 2026

Biotech & Pharma Updates | October 15, 2026

Biotech & Pharma Updates | October 14, 2026

Biotech & Pharma Updates | October 13, 2026

Biotech & Pharma Updates | October 9, 2026

Biotech & Pharma Updates | October 8, 2026

Biotech & Pharma Updates | October 7, 2026

TLDR Biotech

FAQ

Media Partners